FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
Executive Summary
Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.
You may also be interested in...
Humira Will Get Advisory Committee Review For Ulcerative Colitis
FDA’s Gastrointestinal Drugs Advisory Committee is scheduled to review Abbott’s sNDA for the TNF blocker Humira Aug. 28.
Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis
Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.